Differential Effect on Two Immobility Responses by Chronic Administration of 1,3-di-o-Tolyl-Guanidine (Sigma Receptor Agonist) in Rats with Neonatal Ventral Hippocampal Lesion


The effect of chronic administration of the sigma agonist: 1,3-di-o-tolyl-guanidine (DTG), in neonatal ventral hippocampal lesioned (nVHL) rats, on the immobility by clamping and dorsal immobility, were investigated. The nVHL increases the duration of immobility by clamping, but does not affect the duration of the dorsal immobility. We found that DTG augments the duration of the dorsal immobility in the unlesioned rats, but does not modify the duration of immobility induced by clamping the neck. DTG also counteracts the increase in the duration of the immobility by clamping produced by nVHL. However, the increase in the duration of the dorsal immobility produced by DTG is counteracted by nVHL. These results are discussed with respect to the differential effect on the two immobility responses tested, suggesting that they are different forms of immobility mediated by different mechanisms although they behaviorally share common characteristics.

Share and Cite:

Jaramillo, B. , Cruz, F. , Vargas, G. , Morales, O. , Flores, G. , Zamudio, S. and Garcés-Ramírez, L. (2014) Differential Effect on Two Immobility Responses by Chronic Administration of 1,3-di-o-Tolyl-Guanidine (Sigma Receptor Agonist) in Rats with Neonatal Ventral Hippocampal Lesion. Pharmacology & Pharmacy, 5, 681-690. doi: 10.4236/pp.2014.57078.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] De La Cruz, F., Junquera, J. and Russek, M. (1987) Ontogeny of Immobility Reactions Elicited by Clamping, Bandaging and Maternal Transports in Rats. Experimental Neurology, 97, 315-326.
[2] De La Cruz, F., Russek, M. and Junquera, J. (1990) Ontogeny of the Endorphinergic and Dopaminergic Modulation on the Immobility Reflex Elicited by Clamping in Rats. International Journal of Psychophysiology, 9, 171-177.
[3] De La Cruz, F. and Uriostegui, T. (1996) The Differential Haloperidol Effect on the Immobility Response Elicited by Clamping, Grasping, Bandaging and Inversión in Guinea Pig, Hamster and Rat. Behavioural Brain Research, 78, 195-199.
[4] Klemm, W.R. (1971) Neurophysiological Studies of the Immobility Reflex (Animal Hypnosis). In: Ehrenpreis, S. and Stalnisky, O.C., Eds., Neurosciences Research, Academic, New York, 165-210.
[5] Rowlet, J.K., Pedigo, N.W. and Bardo, M.T. (1991) Catalepsy Produced by Striatal Microinjections of the D1 Dopamine Receptor Agonist SCH 23390 in Neonatal Rats. Pharmacology Biochemistry and Behavior, 40, 829-834.
[6] Teitelbaum, P., Wolgin, D.L., De Ryck, M. and Marin, O.S.M. (1976) Bandage Backfall Reaction: Occurs in Infancy, Hypothalamic Damage, and Catalepsy. Proceeding of the National Academic of Sciences of the USA, 73, 3311-3314.
[7] De la Cruz, F., Uriostegui, T., Zamudio, S., Pacheco, J., Quevedo, L. and Chuc, E. (1995) Potentiation of the Imobility Response Elicited by Bandaging and Clamping in Mesencephalic Rats. Physiology & Behavior, 58, 737-742.
[8] Regier, D.A., Narrow, W.E., Rae, D.S., Manderscheid, R.W., Locke, B.Z. and Goodwin, F.K. (1993) The de Facto US Mental and Addictive Disorders Service System. Epidemiologic Catchment Area Prospective 1-Year Prevalence Rates of Disorders and Services. Archives of General Psychiatry, 50, 85-94.
[9] Flores, G., Barbeau, D., Quirion, R. and Srivastava, L.K. (1996) Decreased Binding of Dopamine D3 Receptors in Limbic Subregions after Neonatal Bilateral Lesion of Rat Hippocampus. The Journal of Neuroscience, 16, 2020-2026.
[10] Lipska, B.K. and Weinberger, D.R. (2000) To Model a Psychiatric Disorder in Animals: Schizophrenia as a Reality Test. Neuropsychopharmacology, 23, 223-239.
[11] Lipska, B.K., Jaskiw, G.E. and Weinberger, D.R. (1993) Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxichippocampal Damage: A Potential Animal Model of Schizophrenia. Neuropsychopharmacology, 9, 67-75.
[12] Sams-Dodd, F., Lipska, B.K. and Weinberger, D.R. (1997) Neonatal Lesions of the Rat Ventral Hippocampus Result in Hyperlocomotion and Deficits in Social Behavior in Adulthood. Psychopharmacology (Berl), 132, 303-310.
[13] Chambers, R.A., Moore, J., McEvoy, J.P. and Levin, E.D. (1996) Cognitive Effects of Neonatal Hippocampal Lesions in a Rat Model of Schizophrenia. Neuropsychopharmacology, 15, 587-594.
[14] Alquicer, G., Morales-Medina, J.C., Quirion, R. and Flores, G. (2008) Postweaning Social Isolation Enhances Morphological Changes in the Neonatal Ventral Hippocampal Lesion Rat Model of Psychosis. Journal of Chemical Neuroanatomy, 35, 179-187.
[15] Flores, G., Silva-Gómez, A.B., Barbeau, D., Srivastava, L.K., Zamudio, S.R. and De La Cruz, F. (2005) Effect of Excitotoxic Lesions of the Neonatal Ventral Hippocampus on the Immobility Response in Rats. Life Sciences, 76, 2339-2348.
[16] Laplante, F., Stevenson, C.W., Gratton, A., Srivastava, L.K. and Quirion, R. (2004) Effects of Neonatal Ventral Hippocampal Lesion in Rats on Stress-Induced Acetylcholine Release in the Prefrontal Cortex. Journal of Neurochemistry, 91, 1473-1482.
[17] Laplante, F., Nakagawasai, O., Srivastava, L.K. and Quirion, R. (2005) Alterations in Behavioral Responses to a Cholinergic Agonist in Post-Pubertal Rats with Neonatal Ventral Hippocampal Lesions: Relationship to Changes in Muscarinic Receptor Levels. Neuropsychopharmacology, 30, 1076-1087.
[18] Tam, S.W. (1983) Naloxone-Inaccessible Sigma Receptor in Rat Central Nervous System. Proceedings of the National Academy of Sciences of the United States of America, 80, 6703-6707.
[19] Weissman, A.D., Casanove, M.F., Kleinman, J.E., London, E.D. and de Souza, E.B. (1991) Selective Loss of Cerebral Cortical Sigma, but Not PCP Binding Sites in Schizophrenia. Biological Psychiatry, 29, 41-54.
[20] Weissman, A.D., Su, T.P., Hedreen, J.C. and London, E.D. (1988) Sigma Receptors in Post-Mortem Human Brains. Journal of Pharmacology and Experimental Therapeutics, 247, 29-33.
[21] Steinfels, G.F. and Tam, S.W. (1989) Selective Sigma Receptor agonist and Antagonist Affect Dopamine Neuronal Activity. European Journal of Pharmacology, 163, 167-170.
[22] Zhang, J., Chiodo, L.A., Wettstein, J.G., Junien, J.L. and Freeman, A.S. (1993) Repeated Administration of Sigma Ligands Alters the Population Activity of Rat Midbrain Dopaminergic Neurons. Synapse, 13, 223-230.
[23] Moison, D., De Deurwaerdère, P., Cagnotto, A., Marrazzo, A., Prezzavento, O., Ronsisvalle, G., et al. (2003) Intrastriatal Administration of Sigma Ligands Inhibits Basal Dopamine Release in Vivo. Neuropharmacology, 45, 945-953.
[24] Garcés-Ramírez, L., Green, J.L., Hiranita, T., Kopajtic, T.A., Mereu, M., Thomas, A.M., Mesangeau, C., Narayanan, S., McCurdy, C.R., Katz, J.L. and Tanda, G. (2011) Sigma Receptor Agonists: Receptor Binding and Effects on Mesolimbic Dopamine Neurotransmission Assessed by Microdialysis. Biological Psychiatry, 69, 208-217.
[25] Shibuya, H., Mori, H. and Toru, M. (1992) Sigma Receptors in Schizophrenic Cerebral Cortices. Neurochemical Research, 17, 983-990.
[26] Su, T.P. (1982) Evidence for Sigma Opioid Receptor: Binding of [3H]SKF-10047 to Etorphine-Inaccesible Sites in Guinea-Pig Brain. Journal of Pharmacology and Experimental Therapeutics, 223, 284-290.
[27] Tam, S.W. and Cook, L. (1984) Sigma Opiates and Certain Antipsychotic Drugs Mutually Inhibit (+)-[3H] SKF 10,047 and [3H]Haloperidol Binding in Guinea Pig Brain Membranes. Proceedings of the National Academy of Sciences of the United States of America, 81, 5618-5621.
[28] Kitaichi, K., Chabot, J.G., Moebius, F.F., Flandorfer, A., Glossmann, H. and Quirion, R. (2000) Expression of the Purported Sigma1 (1) Receptor in the Mammalian Brain and Its Possible Relevance in Deficits Induced by Antagonism of the NMDA Receptor Complex as Revealed Using an Antisense Strategy. Journal of Chemical Neuroanatomy, 20, 375-387.
[29] Shimazu, S., Katsuki, H., Takenaka, C., Tomita, M., Kume, T., Kaneko, S., et al. (2000) Sigma Receptor Ligands Attenuate N-Methyl-D-Aspartate Cytotoxicity in Dopaminergic Neurons of Mesencephalic Slice Cultures. European Journal of Pharmacology, 388, 139-146.
[30] Goff, D.C. and Coyle, J.T. (2001) The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia. The American Journal of Psychiatry, 158, 1367-1377.
[31] Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., et al. (2003) Decreased Serum Levels of D-Serine in Patients with Schizophrenia: Evidence in Support of the N-Methyl-D-Aspartate Receptor Hypofunction Hypothesis of Schizophrenia. Archives of General Psychiatry, 60, 572-576.
[32] Hashimoto, K., Okamura, N., Shimizu, E. and Iyo, M. (2004) Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs. Current Medicinal Chemistry, Central Nervous System Agents, 4, 147-154.
[33] Hashimoto, K. (2006) The NMDA Receptor Hypofunction Hypothesis for Schizophrenia and Glycinemodulatory Sites on the NMDA Receptors as Potential Therapeutic Drugs. Clinical Psychopharmacology and Neuroscience, 4, 3-10.
[34] Martín, W.R., Eades, C.G. and Thompson, J.A. (1976) The Effects of Morphine and Nalorphine-Like Drugs in Nondependent and Morphine Dependent Chronic Spinal Dog. Journal of Pharmacology and Experimental Therapeutics, 197, 517-535.
[35] Quirion, R., Bowen, W.D., Itzhak, Y., Junien, J.L., Musacchio, J.M., Rothman, R.B., et al. (1992) A Proposal for the Classification of Sigma Binding Sites. Trends in Pharmacological Sciences, 13, 85-86.
[36] Bowen, W.D., Hellewell, S.B. and McGarry, K.A. (1989) Evidence for a Multi-Site Model of the Rat Brain Sigma Receptor. European Journal of Pharmacology, 163, 309-318.
[37] Hanner, M., Moebius, F., Flandorfer, A., Knaus, H.G., Striessnig, J., Kempner, E., et al. (1996) Purification, Molecular Cloning and Expression of the Mammalian sigma1-Binding Site. Proceedings of the National Academy of Sciences of the United States of America, 93, 8072-8077.
[38] Hayashi, T. and Su, T.P. (2003) Intracellular Dynamics of sigma-1 Receptors (sigma1 Binding Sites) in NG108-15 Cells. Journal of Pharmacology and Experimental Therapeutics, 306, 726-733.
[39] Hayashi, T. and Su, T.P. (2003) Sigma-1 Receptors (sigma1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export. Journal of Pharmacology and Experimental Therapeutics, 306, 718-725.
[40] Heroux, J.A., Tam, S.W. and De Souza, E.B. (1992) Autoradiographic Identification and Characterization of Sigma Receptors in Guinea Pig Brain Using [3H]1(Cyclopropylmethyl)-4-(2’-(4≈-Fluorophenyl)-2’-Oxoethyl) Piperidine ([3H]DuP 734), a Novel Sigma Receptor Ligand. Brain Research, 598, 76-86.
[41] Hayashi, T. and Su, T.P. (2007) Sigma-1 Receptor Chaperones at the ER-Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival. Cell, 131, 596-610.
[42] Hayashi, T. and Su, T.P. (2004) Sigma-1 Receptors at Galactosylceramide-Enriched Lipid Microdomains Regulatesoligodendrocyte Differentiation. Proceedings of the National Academy of Sciences of the United States of America, 101, 14949-14954. http://dx.doi.org/10.1073/pnas.0402890101
[43] Hayashi, T. and Su, T.P. (2008) An Update on the Development of Drugs for Neuropsychiatric Disorders: Focusing on the Sigma(1) Receptor Ligand. Expert Opinion on Therapeutic Targets, 12, 45-58.
[44] Takebayashi, M., Hayashi, T. and Su, T.P. (2004) A Perspective on the New Mechanism of Antidepressants: Neuritogenesis through Sigma-1 Receptors. Pharmacopsychiatry, 37, 208-213. http://dx.doi.org/10.1055/s-2004-832679
[45] Tsai, Y.K., Hayashi, T., Harvey, B.K., Wang, Y., Su, P.T., et al. (2009) Sigma-1 Receptors Regulate Hippocampaldendritic Spine Formation via a Free Radical-Sensitive Mechanism Involving Rac1 GTP Pathway. Proceedings of the National Academy of Sciences of the United States of America, 106, 22468-22473.
[46] Maurice, T. and Lockhart, B.P. (1997) Neuroprotective and Anti-Amnesic Potentials of Sigma Receptor Ligands. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 21, 69-102.
[47] Marrazzo, A., Caraci, F., Salinaro, E.T., Su, T.P., Copani, A. and Ronsisvalle, G. (2005) Neuroprotective Effects of sigma-1 Receptor Agonists against Beta-Amyloid-Induced Toxicity. Neuroreport, 16, 1223-1226.
[48] Maurice, T. (2007) Cognitive Effects of Sigma-Receptor Ligands. In: Matsumoto, R.R., Bowen, W.D. and Su, T.P., Eds., Sigma Receptors: Chemistry, Cell Biology and Clinical Implications, Chap. 12, Springer, New York, 237-271.
[49] Sierra, A., Camacho-Abrego, I., Escamilla, C., Negrete-Diaz, J.V., Rodriguez-Sosa, L. and Flores, G. (2009) Economical Body Platform for Neonatal Rats Stereotaxic Surgery. Revista de Neurología, 48, 141-146.
[50] Weber, E., Sonders, M., Quarum, M., McLean, S., Pou, S. and Keana, J.F. (1986) 1,3-Di(2-tolyl)guanidine: A Selective Ligand That Labels Sigma-Type Receptors for Psychotomimetic Opiates and Antipsychotic Drugs. Proceedings of the National Academy of Sciences of the United States of America, 83, 8784-8788.
[51] Brake, W.G., Sullivan, R.M., Flores, G., Srivastava, L.K. and Gratton, A. (1999) Neonatal Ventral Hippocampal Lesions Attenuate the Nucleus Accumbens Dopamine Response to Stress: An Electrochemical Study in the Adult Rat. Brain Research, 831, 25-32.
[52] Silva-Gomez, A.B., Bermudez, M., Quirion, R., Srivastava, L.K., Picazo, O. and Flores, G. (2003) Comparative Behavioral Changes between Male and Female Postpubertal Rats Following Neonatal Excitotoxic Lesions of the Ventral Hippocampus. Brain Research, 973, 285-292.
[53] Paxinos, G. and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
[54] Ornstein, K. and Amir, G. (1981) Pinch Induced Catalepsy in Mice. Journal of Comparative and Physiological, 95, 827-835.
[55] Ornstein, K. (1981) Suppression of Wet-Dog Shakes by Tail and Scruff Pinch. Physiology & Behavior, 27, 13-17.
[56] Soper, W. and Melzack, R. (1981) Stimulation Produced Analgesia: Evidence for Somatotopic Organization in the Midbrain. Brain Research, 251, 301-313.
[57] Miranda, A., De La Cruz, F. and Zamudio, S.R. (2006) Immobility Response Elicited by Clamping the Neck Induces Antinociception in a “Tonic Pain” Test in Mice. Life Science, 79, 1108-1113.
[58] De Ryck, M., Schallert, T. and Teitelbaum, P. (1980) Morphine versus Haloperidol Catalepsy in the Rat: A Behavioral Analysis of Postural Mechanisms. Brain Research, 201, 143-172.
[59] Blasing, J. (1978) On the Role of Brain Catecholamines in Acute and Chronic Opiate Action. In: Herz, A., Ed., Developments in Opiate Research, Dekker, New York, 279-356.
[60] Fregoso-Aguilar, T., Urióstegui, T., Zamudio, S. and De la Cruz, F. (2002) The Differential Effect of Haloperidol and Repetitive Induction on Four Immobility Responses in Mouse and Guinea Pig. Behavioural Pharmacology, 13, 253-260.
[61] Dhir, A. and Kulkarni, S.K. (2008) Possible Involvement of Sigma-1 Receptors in the Anti-Immobility Action of Bupropion, a Dopamine Reuptake Inhibitor. Fundamental & Clinical Pharmacology, 22, 387-394.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.